Glaukos.
public company
- Reports this week
- 2
- Active events
- 1
- Connections
- 36
What's happening
Active this week
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Glaukos markets FDA-approved corneal cross-linking therapy, with management attending a conference in Boston.Well supported6 reports
-
Glaukos CFO Alex R. Thurman sold shares of the company's stock.Some support1 report
-
Analyst firm assumed coverage on Glaukos shares.Some support1 report
-
Citigroup raised its price target and gave a buy rating for Glaukos, while Leana Wen sold Glaukos stock.Some support1 report
-
Thomas Burns was appointed CEO and chairman of Glaukos, noting that EU certification is key to maintaining the company's presence in Europe.Some support5 reports
-
Glaukos shares underperformed the S&P 500 on July 31, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Glaukos this week
News at the entities that move Glaukos most-
FDA StructuralAjay Devgn challenged a notice in the High Court while the FDA enforced state rules in Maharashtra.Moves Glaukos
-
Citigroup TransactionalCitigroup reduced its price objective for ProKidney, with stock changes and ratings reported by Benzinga and MarketBeat.Moves Glaukos
-
Royal Bank of Canada TransactionalRoyal Bank of Canada boosted its stake in the S&P ETF on October 31, 2026.Moves Glaukos
-
Abbott Laboratories OperationalAbbVie and Abbott Laboratories are large healthcare companies whose corporate histories are linked by a major split that occurred in 2013.Moves Glaukos
-
Needham & Company Mentioned togetherOPay ADSs are expected to trade on the New York Stock Exchange, with Needham & Company acting as co-manager.Moves Glaukos
-
SEC StructuralRadNet filed required reports with the SEC and traded on the Nasdaq stock exchange.Moves Glaukos
Connections
The 13 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Tom Burns Structural
Tom Burns holds the formal leadership roles of Chairman and CEO of Glaukos.
-
Thomas Burns Structural
Thomas Burns serves as the Chairman and CEO of Glaukos.
-
FDA Structural
Glaukos's ability to market its products is dependent on receiving formal approval from the FDA.
-
Chris Lewis Structural
Chris Lewis serves as VP of Investor Relations for Glaukos.
-
SEC Structural
Glaukos is subject to regulatory oversight by the SEC regarding its stock holdings and required filings.
-
Royal Bank of Canada Transactional
Royal Bank of Canada has increased its holdings in Glaukos Corporation stock.
-
curry Operational
Curry and Glaukos collaborated on a joint awareness campaign.
-
FactSet Operational
Glaukos's revenue performance is tracked and compared against consensus estimates provided by FactSet.
Show all 13 connections
-
Citigroup Transactional
Citigroup assessed Glaukos by raising its price target and assigning a buy rating.
-
Aliso Viejo Shared context
The company is located in Aliso Viejo, California.
-
Needham & Company Mentioned together
Needham & Company provides analyst coverage on Glaukos shares.
-
Leana Wen Transactional
Leana Wen sold shares of Glaukos stock.
-
Abbott Laboratories Operational
Both Abbott Laboratories and Glaukos actively compete within the medical device stock market.
History
Events by the month they beganOctober 2026
2 eventsAugust 2026
2 eventsJuly 2026
3 eventsShow 1 earlier month
June 2026
3 events- Glaukos markets FDA-approved corneal cross-linking therapy, with management attending a conference in Boston.
- Thomas Burns was appointed CEO and chairman of Glaukos, noting that EU certification is key to maintaining the company's presence in Europe.
- Glaukos shares underperformed the S&P 500 on July 31, 2025.